Capstone Financial Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$858K Buy
715
+88
+14% +$89.9K 0.04% 77
2026
Q1
$576K Buy
627
+12
+2% +$12.2K 0.03% 92
2025
Q4
$661K Buy
615
+1
+0.2% +$956 0.04% 80
2025
Q3
$469K Buy
614
+230
+60% +$171K 0.03% 101
2025
Q2
$299K Buy
384
+52
+16% +$40.4K 0.02% 124
2025
Q1
$274K Sell
332
-82
-20% -$68.2K 0.02% 121
2024
Q4
$320K Sell
414
-1,528
-79% -$1.27M 0.02% 115
2024
Q3
$1.72M Buy
1,942
+1,250
+181% +$1.12M 0.11% 42
2024
Q2
$626K Buy
692
+64
+10% +$51.2K 0.04% 73
2024
Q1
$489K Buy
628
+189
+43% +$135K 0.03% 85
2023
Q4
$256K Buy
439
+3
+0.7% +$1.75K 0.02% 115
2023
Q3
$234K Sell
436
-59
-12% -$30.4K 0.02% 114
2023
Q2
$232K Buy
+495
New +$208K 0.02% 114

Other funds holding LLY

Capstone Financial Advisors's LLY Position: Q2 2026 in Review

Capstone Financial Advisors increased its Eli Lilly (LLY) stake by 14% in Q2 2026, buying an estimated $89.9K and bringing the position to 715 shares worth $858K. The position accounts for 0.04% of the portfolio, ranked #77.

Capstone Financial Advisors first reported a position in LLY in Q2 2023 and has held it in 13 quarters since. The position peaked at $1.72M in Q3 2024. 4,624 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Capstone Financial Advisors held 715 shares of Eli Lilly worth $858K as of Q2 2026.
  • Capstone Financial Advisors bought 88 Eli Lilly shares in Q2 2026, an estimated $89.9K.
  • Eli Lilly made up 0.04% of Capstone Financial Advisors's portfolio in Q2 2026, its #77 holding.
  • Capstone Financial Advisors first reported a position in Eli Lilly in Q2 2023 and has held it in 13 quarters since.
  • Capstone Financial Advisors's Eli Lilly position peaked at $1.72M in Q3 2024.
  • 4,624 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Capstone Financial Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.